Abiopharma

🔍 Shea-Ballay Kathleen (Executive)

Company: UGI CORP /PA/ (UGI)

Report Date: 2026-06-18

Detailed Transactions and Holdings:

• Acquired 25,360 shares of UGI Common Stock at $24.6 per share (Direct)
  Date: 2026-06-18 | Code: M | equity_swap_involved: 0 | shares_owned_after: 25,360.00 | transaction_form_type: 4
• Sold 25,360 shares of UGI Common Stock at $33.6157 per share (Direct)
  Date: 2026-06-18 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 25,360 shares of Options (Right to Buy) at $24.6 per share (Derivative)
  Date: 2026-06-18 | Code: M | Expires: 2033-12-31 | Exercise: 2025-01-01 | equity_swap_involved: 0 | shares_owned_after: 12,680.00 | transaction_form_type: 4

Footnotes:

• F1: The shares of common stock with respect to this transaction were purchased at prices ranging from $33.58 and $33.89. Upon request, UGI Corporation will provide to the U.S. Securities and Exchange Commission staff, or a security holder of UGI Corporation, full information regarding the number of shares of common stock purchased at each separate price.